 | • レポートコード：GIR-107A12578 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、101ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、乳がん用PI3K/AKT/mTor経路阻害剤のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。乳がん用PI3K/AKT/mTor経路阻害剤の種類別市場規模（テムシロリムス、エベロリムス）、用途別市場規模（病院、クリニック、ドラッグセンター、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・乳がん用PI3K/AKT/mTor経路阻害剤の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Pfizer、Gland Pharma、Accord Healthcare、Novartis、Glenmark Pharmaceuticals、Cipla、Dr Reddy's Laboratories、Natco Pharma、Intas Pharmaceuticals、Panacea Biotec、Alkem Laboratories、Biocon Pharma ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：テムシロリムス、エベロリムス ・用途別分析2016年-2026年：病院、クリニック、ドラッグセンター、その他 ・乳がん用PI3K/AKT/mTor経路阻害剤の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・乳がん用PI3K/AKT/mTor経路阻害剤のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・乳がん用PI3K/AKT/mTor経路阻害剤のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・乳がん用PI3K/AKT/mTor経路阻害剤の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・乳がん用PI3K/AKT/mTor経路阻害剤の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Temsirolimus
Everolimus
Market segment by Application, can be divided into
Hospital
Clinic
Drug Center
Other
Market segment by players, this report covers
Pfizer
Gland Pharma
Accord Healthcare
Novartis
Glenmark Pharmaceuticals
Cipla
Dr Reddy’s Laboratories
Natco Pharma
Intas Pharmaceuticals
Panacea Biotec
Alkem Laboratories
Biocon Pharma
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer
1.2 Classification of PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer by Type
1.2.1 Overview: Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue Market Share by Type in 2020
1.2.3 Temsirolimus
1.2.4 Everolimus
1.3 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market by Application
1.3.1 Overview: Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Drug Center
1.3.5 Other
1.4 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size & Forecast
1.5 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size and Forecast by Region
1.5.1 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Region, (2016-2021)
1.5.3 North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size and Prospect (2016-2026)
1.5.4 Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size and Prospect (2016-2026)
1.5.6 South America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Drivers
1.6.2 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Restraints
1.6.3 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Trends Analysis
2 Company Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Solutions
2.1.4 Pfizer PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Pfizer Recent Developments and Future Plans
2.2 Gland Pharma
2.2.1 Gland Pharma Details
2.2.2 Gland Pharma Major Business
2.2.3 Gland Pharma PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Solutions
2.2.4 Gland Pharma PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Gland Pharma Recent Developments and Future Plans
2.3 Accord Healthcare
2.3.1 Accord Healthcare Details
2.3.2 Accord Healthcare Major Business
2.3.3 Accord Healthcare PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Solutions
2.3.4 Accord Healthcare PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Accord Healthcare Recent Developments and Future Plans
2.4 Novartis
2.4.1 Novartis Details
2.4.2 Novartis Major Business
2.4.3 Novartis PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Solutions
2.4.4 Novartis PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Novartis Recent Developments and Future Plans
2.5 Glenmark Pharmaceuticals
2.5.1 Glenmark Pharmaceuticals Details
2.5.2 Glenmark Pharmaceuticals Major Business
2.5.3 Glenmark Pharmaceuticals PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Solutions
2.5.4 Glenmark Pharmaceuticals PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Glenmark Pharmaceuticals Recent Developments and Future Plans
2.6 Cipla
2.6.1 Cipla Details
2.6.2 Cipla Major Business
2.6.3 Cipla PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Solutions
2.6.4 Cipla PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Cipla Recent Developments and Future Plans
2.7 Dr Reddy’s Laboratories
2.7.1 Dr Reddy’s Laboratories Details
2.7.2 Dr Reddy’s Laboratories Major Business
2.7.3 Dr Reddy’s Laboratories PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Solutions
2.7.4 Dr Reddy’s Laboratories PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Dr Reddy’s Laboratories Recent Developments and Future Plans
2.8 Natco Pharma
2.8.1 Natco Pharma Details
2.8.2 Natco Pharma Major Business
2.8.3 Natco Pharma PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Solutions
2.8.4 Natco Pharma PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Natco Pharma Recent Developments and Future Plans
2.9 Intas Pharmaceuticals
2.9.1 Intas Pharmaceuticals Details
2.9.2 Intas Pharmaceuticals Major Business
2.9.3 Intas Pharmaceuticals PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Solutions
2.9.4 Intas Pharmaceuticals PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Intas Pharmaceuticals Recent Developments and Future Plans
2.10 Panacea Biotec
2.10.1 Panacea Biotec Details
2.10.2 Panacea Biotec Major Business
2.10.3 Panacea Biotec PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Solutions
2.10.4 Panacea Biotec PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Panacea Biotec Recent Developments and Future Plans
2.11 Alkem Laboratories
2.11.1 Alkem Laboratories Details
2.11.2 Alkem Laboratories Major Business
2.11.3 Alkem Laboratories PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Solutions
2.11.4 Alkem Laboratories PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Alkem Laboratories Recent Developments and Future Plans
2.12 Biocon Pharma
2.12.1 Biocon Pharma Details
2.12.2 Biocon Pharma Major Business
2.12.3 Biocon Pharma PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Solutions
2.12.4 Biocon Pharma PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Biocon Pharma Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Players Market Share
3.2.2 Top 10 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Players Market Share
3.2.3 Market Competition Trend
3.3 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue and Market Share by Type (2016-2021)
4.2 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue Market Share by Application (2016-2021)
5.2 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Type (2016-2026)
6.2 North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Application (2016-2026)
6.3 North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Country
6.3.1 North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Country (2016-2026)
6.3.2 United States PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size and Forecast (2016-2026)
6.3.3 Canada PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size and Forecast (2016-2026)
6.3.4 Mexico PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Type (2016-2026)
7.2 Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Application (2016-2026)
7.3 Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Country
7.3.1 Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Country (2016-2026)
7.3.2 Germany PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size and Forecast (2016-2026)
7.3.3 France PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size and Forecast (2016-2026)
7.3.4 United Kingdom PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size and Forecast (2016-2026)
7.3.5 Russia PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size and Forecast (2016-2026)
7.3.6 Italy PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Type (2016-2026)
8.2 Asia-Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Application (2016-2026)
8.3 Asia-Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Region
8.3.1 Asia-Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Region (2016-2026)
8.3.2 China PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size and Forecast (2016-2026)
8.3.3 Japan PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size and Forecast (2016-2026)
8.3.4 South Korea PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size and Forecast (2016-2026)
8.3.5 India PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size and Forecast (2016-2026)
8.3.7 Australia PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Type (2016-2026)
9.2 South America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Application (2016-2026)
9.3 South America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Country
9.3.1 South America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Country (2016-2026)
9.3.2 Brazil PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size and Forecast (2016-2026)
9.3.3 Argentina PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Type (2016-2026)
10.2 Middle East & Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Application (2016-2026)
10.3 Middle East & Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Country
10.3.1 Middle East & Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Country (2016-2026)
10.3.2 Turkey PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size and Forecast (2016-2026)
10.3.4 UAE PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue (USD Million) by Region (2016-2021)
Table 5. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue Market Share by Region (2021-2026)
Table 6. Pfizer Corporate Information, Head Office, and Major Competitors
Table 7. Pfizer Major Business
Table 8. Pfizer PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Solutions
Table 9. Pfizer PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Gland Pharma Corporate Information, Head Office, and Major Competitors
Table 11. Gland Pharma Major Business
Table 12. Gland Pharma PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Solutions
Table 13. Gland Pharma PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Accord Healthcare Corporate Information, Head Office, and Major Competitors
Table 15. Accord Healthcare Major Business
Table 16. Accord Healthcare PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Solutions
Table 17. Accord Healthcare PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Novartis Corporate Information, Head Office, and Major Competitors
Table 19. Novartis Major Business
Table 20. Novartis PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Solutions
Table 21. Novartis PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Glenmark Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 23. Glenmark Pharmaceuticals Major Business
Table 24. Glenmark Pharmaceuticals PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Solutions
Table 25. Glenmark Pharmaceuticals PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Cipla Corporate Information, Head Office, and Major Competitors
Table 27. Cipla Major Business
Table 28. Cipla PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Solutions
Table 29. Cipla PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Dr Reddy's Laboratories Corporate Information, Head Office, and Major Competitors
Table 31. Dr Reddy's Laboratories Major Business
Table 32. Dr Reddy's Laboratories PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Solutions
Table 33. Dr Reddy's Laboratories PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Natco Pharma Corporate Information, Head Office, and Major Competitors
Table 35. Natco Pharma Major Business
Table 36. Natco Pharma PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Solutions
Table 37. Natco Pharma PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Intas Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 39. Intas Pharmaceuticals Major Business
Table 40. Intas Pharmaceuticals PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Solutions
Table 41. Intas Pharmaceuticals PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Panacea Biotec Corporate Information, Head Office, and Major Competitors
Table 43. Panacea Biotec Major Business
Table 44. Panacea Biotec PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Solutions
Table 45. Panacea Biotec PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Alkem Laboratories Corporate Information, Head Office, and Major Competitors
Table 47. Alkem Laboratories Major Business
Table 48. Alkem Laboratories PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Solutions
Table 49. Alkem Laboratories PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Biocon Pharma Corporate Information, Head Office, and Major Competitors
Table 51. Biocon Pharma Major Business
Table 52. Biocon Pharma PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Solutions
Table 53. Biocon Pharma PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue (USD Million) by Players (2019-2021)
Table 55. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue Share by Players (2019-2021)
Table 56. Breakdown of PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer by Company Type (Tier 1, Tier 2 and Tier 3)
Table 57. PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Players Head Office, Products and Services Provided
Table 58. PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Mergers & Acquisitions in the Past Five Years
Table 59. PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer New Entrants and Expansion Plans
Table 60. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue (USD Million) by Type (2016-2021)
Table 61. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue Share by Type (2016-2021)
Table 62. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue Forecast by Type (2021-2026)
Table 63. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Application (2016-2021)
Table 64. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue Forecast by Application (2021-2026)
Table 65. North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Type (2016-2021) & (USD Million)
Table 66. North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Type (2021-2026) & (USD Million)
Table 67. North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Application (2016-2021) & (USD Million)
Table 68. North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Application (2021-2026) & (USD Million)
Table 69. North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Country (2016-2021) & (USD Million)
Table 70. North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Country (2021-2026) & (USD Million)
Table 71. Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Type (2016-2021) & (USD Million)
Table 72. Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Type (2021-2026) & (USD Million)
Table 73. Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Application (2016-2021) & (USD Million)
Table 74. Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Application (2021-2026) & (USD Million)
Table 75. Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Country (2016-2021) & (USD Million)
Table 76. Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Country (2021-2026) & (USD Million)
Table 77. Asia-Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Type (2016-2021) & (USD Million)
Table 78. Asia-Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Type (2021-2026) & (USD Million)
Table 79. Asia-Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Application (2016-2021) & (USD Million)
Table 80. Asia-Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Application (2021-2026) & (USD Million)
Table 81. Asia-Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Region (2016-2021) & (USD Million)
Table 82. Asia-Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Region (2021-2026) & (USD Million)
Table 83. South America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Type (2016-2021) & (USD Million)
Table 84. South America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Type (2021-2026) & (USD Million)
Table 85. South America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Application (2016-2021) & (USD Million)
Table 86. South America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Application (2021-2026) & (USD Million)
Table 87. South America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Country (2016-2021) & (USD Million)
Table 88. South America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Country (2021-2026) & (USD Million)
Table 89. Middle East & Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Type (2016-2021) & (USD Million)
Table 90. Middle East & Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Type (2021-2026) & (USD Million)
Table 91. Middle East & Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Application (2016-2021) & (USD Million)
Table 92. Middle East & Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Application (2021-2026) & (USD Million)
Table 93. Middle East & Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Country (2016-2021) & (USD Million)
Table 94. Middle East & Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Picture
Figure 2. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue Market Share by Type in 2020
Figure 3. Temsirolimus
Figure 4. Everolimus
Figure 5. PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue Market Share by Application in 2020
Figure 6. Hospital Picture
Figure 7. Clinic Picture
Figure 8. Drug Center Picture
Figure 9. Other Picture
Figure 10. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 11. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue and Forecast (2016-2026) & (USD Million)
Figure 12. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue Market Share by Region (2016-2026)
Figure 13. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue Market Share by Region in 2020
Figure 14. North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Asia-Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. South America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Middle East and Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Drivers
Figure 20. PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Restraints
Figure 21. PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Trends
Figure 22. Pfizer Recent Developments and Future Plans
Figure 23. Gland Pharma Recent Developments and Future Plans
Figure 24. Accord Healthcare Recent Developments and Future Plans
Figure 25. Novartis Recent Developments and Future Plans
Figure 26. Glenmark Pharmaceuticals Recent Developments and Future Plans
Figure 27. Cipla Recent Developments and Future Plans
Figure 28. Dr Reddy's Laboratories Recent Developments and Future Plans
Figure 29. Natco Pharma Recent Developments and Future Plans
Figure 30. Intas Pharmaceuticals Recent Developments and Future Plans
Figure 31. Panacea Biotec Recent Developments and Future Plans
Figure 32. Alkem Laboratories Recent Developments and Future Plans
Figure 33. Biocon Pharma Recent Developments and Future Plans
Figure 34. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue Share by Players in 2020
Figure 35. PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 36. Global Top 3 Players PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue Market Share in 2020
Figure 37. Global Top 10 Players PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue Market Share in 2020
Figure 38. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 39. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue Share by Type in 2020
Figure 40. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share Forecast by Type (2021-2026)
Figure 41. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue Share by Application in 2020
Figure 42. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share Forecast by Application (2021-2026)
Figure 43. North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales Market Share by Type (2016-2026)
Figure 44. North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales Market Share by Application (2016-2026)
Figure 45. North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue Market Share by Country (2016-2026)
Figure 46. United States PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Canada PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. Mexico PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales Market Share by Type (2016-2026)
Figure 50. Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales Market Share by Application (2016-2026)
Figure 51. Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue Market Share by Country (2016-2026)
Figure 52. Germany PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. France PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. United Kingdom PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Russia PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Italy PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Asia-Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales Market Share by Type (2016-2026)
Figure 58. Asia-Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales Market Share by Application (2016-2026)
Figure 59. Asia-Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue Market Share by Region (2016-2026)
Figure 60. China PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Japan PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. South Korea PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. India PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Southeast Asia PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Australia PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. South America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales Market Share by Type (2016-2026)
Figure 67. South America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales Market Share by Application (2016-2026)
Figure 68. South America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue Market Share by Country (2016-2026)
Figure 69. Brazil PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Argentina PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Middle East and Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales Market Share by Type (2016-2026)
Figure 72. Middle East and Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales Market Share by Application (2016-2026)
Figure 73. Middle East and Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue Market Share by Country (2016-2026)
Figure 74. Turkey PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Saudi Arabia PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. UAE PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Methodology
Figure 78. Research Process and Data Source
世界のがんmTOR阻害剤市場 2021：企業別、地域別、種類・用途別 The Cancer mTOR Inhibitors market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulati…- 世界の乳がん用CDK4/6阻害薬市場 2021：企業別、地域別、種類・用途別 The CDK4/6 Inhibitors for Breast Cancer market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, t…
- 世界の乳がん用アロマターゼ阻害剤市場 2021：企業別、地域別、種類・用途別 The Aromatase Inhibitors for Breast Cancer market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization…
- 世界の乳がん治療薬市場 2021：企業別、地域別、種類・用途別 The Breast Cancer Treatment Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade r…
- 世界のがん用PARP阻害剤市場 2021：企業別、地域別、種類・用途別 The PARP Inhibitors for Cancer market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regu…